Ironwood Pharmaceuticals (IRWD) Receivables (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Receivables across 17 years of filings, most recently posting $105.8 million for Q1 2026.

• Receivables for Q1 2026 came in at $105.8 million, up 165.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $105.8 million (up 165.83% YoY), and the FY2025 annual result was $46.7 million, down 42.92% from the prior year.
• Receivables came in at $105.8 million for Q1 2026 at Ironwood Pharmaceuticals, up from $46.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $131.0 million in Q3 2022 to a low of $39.8 million in Q1 2025.
• The 5-year median for Receivables is $115.7 million (2023), against an average of $98.4 million.
• Across the five-year window, Receivables slumped 51.18% in 2024 and surged 165.83% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Receivables stood at $130.0 million in 2022, then decreased by 0.69% to $129.1 million in 2023, then plunged by 36.56% to $81.9 million in 2024, then plunged by 42.92% to $46.7 million in 2025, then soared by 126.33% to $105.8 million in 2026.
• The last three Receivables figures came in at $105.8 million (Q1 2026), $46.7 million (Q4 2025), and $120.4 million (Q3 2025), per Business Quant data.